Department of Infectious Diseases, Rostov State Medical University, 344022 Rostov on the Don, Russia.
Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrücken, Germany; Saarbrücken Graduate School of Computer Science, Saarland University, 66123 Saarbrücken, Germany.
J Clin Virol. 2016 Aug;81:82-9. doi: 10.1016/j.jcv.2016.05.010. Epub 2016 May 24.
HCV affects 185 million people worldwide and leads to death and morbidities. HCV has a high genetic diversity and is classified into seven genotypes and 67 subtypes. Novel anti-HCV drugs (Direct-Acting-Antivirals) eligibility, resistance and cure rates depend on HCV geno/subtype (GT).
Analysis of epidemiological information and viral GT from patients undergoing viral genotyping in 2011-2015.
Anonymized information from 52 centers was analyzed retrospectively.
37,839 samples were included in the study. We show that the GT distribution is similar throughout Western European countries, with some local differences. Here GTs 1 and 2 prevalences are lower and of GT4 higher than in all previous reports. Israel has a unique GT pattern and in South Russia the GT proportions are more similar to Asia. GTs 5 and 6 were detected in very low proportions. Three cases of the recombinant genotype P were reported in Munich (Germany). In addition, we observed that GT proportion was dependant on patientś gender, age and transmission route: GTs 1b and 2 were significantly more common in female, older, nosocomially-infected patients, while GTs 1a, 3 and 4 were more frequent in male, younger patients infected by tattooing, drug consume, and/or sexual practices. In infections acquired by drug consume, GTs 1a (35.0%) and 3 (28.1%) prevailed. In infections related to sexual practices lower proportion of GT3 (14.0%) and higher of GT4 (20.2%) were detected. GT4 was mostly abundant in MSM (29.6%). HIV coinfection was significantly associated with higher proportions GTs 1a and 4 (42.5% and 19.3%, respectively).
Genotype prevalence evolves and correlates to epidemiological factors. Continuous surveillance is necessary to better assess hepatitis C infection in Europe and to take appropriate actions.
HCV 影响全球 1.85 亿人，并导致死亡和发病。HCV 具有高度的遗传多样性，分为 7 个基因型和 67 个亚型。新型抗 HCV 药物（直接作用抗病毒药物）的适用性、耐药性和治愈率取决于 HCV 基因型/亚型（GT）。
分析 2011 年至 2015 年接受病毒基因分型的患者的流行病学信息和病毒 GT。
对 52 个中心的匿名信息进行回顾性分析。
本研究共纳入 37839 例样本。我们表明，GT 分布在整个西欧国家相似，但存在一些局部差异。这里 GT1 和 GT2 的流行率较低，GT4 的流行率较高，与以往所有报告均不同。以色列具有独特的 GT 模式，而在俄罗斯南部，GT 比例与亚洲更为相似。GT5 和 GT6 的检出率非常低。在德国慕尼黑报告了 3 例重组基因型 P 的病例。此外，我们还观察到 GT 比例与患者的性别、年龄和传播途径有关：GT1b 和 GT2 在女性、年龄较大、医院感染的患者中更为常见，而 GT1a、GT3 和 GT4 在男性、年龄较小、通过纹身、药物滥用和/或性接触感染的患者中更为常见。在药物滥用相关感染中，GT1a（35.0%）和 GT3（28.1%）更为常见。在与性接触相关的感染中，GT3（14.0%）的比例较低，而 GT4（20.2%）的比例较高。GT4 在男同性恋者（MSM）中最为丰富（29.6%）。HIV 合并感染与 GT1a 和 GT4 的比例较高显著相关（分别为 42.5%和 19.3%）。
基因型流行情况不断演变，并与流行病学因素相关。需要持续监测以更好地评估欧洲的 HCV 感染，并采取适当的措施。
